Topic: Women’s Health

Social Media Recruitment: Lessons from Two Studies with Different Results

Social media are useful recruitment tools but results vary, especially as to the quality of subjects. Examples from two recent Health Decisions trials illustrate. We utilized a variety of social media in both trials, including craigslist, Facebook, a social media recruitment vendor’s sites and investigators’ social media sites. In one study, social media accounted for… Read more »

Saluting Trial Participants on International Clinical Trials Day

In observing International Clinical Trials Day for 2017 on May 19, Health Decisions wishes to thank all those who participate in clinical trials. Health Decisions especially thanks patients enrolled in our current trials but we want to thank trial participants everywhere for making clinical development possible. While sponsors and CROs like Health Decisions make every… Read more »

Women’s Health Week 2017: Spotlight on Infectious Conditions

For National Women’s Health Week last year, this blog focused on the need for progress in a variety of areas in which women have unmet medical needs. Last year’s post mentioned the need for progress in noninvasive diagnostics and therapeutics for osteoporosis, female sexual dysfunction, endometriosis, bacterial vaginosis and uterine fibroids. This year we want… Read more »

Thinking of Women’s Healthcare Needs on International Women’s Day

As a CRO focused on clinical development of products to improve women’s healthcare, Health Decisions sees International Women’s Day as an occasion to redouble our commitment to enabling drug, diagnostics and medical device companies to bring new women’s health products to market as rapidly and efficiently as possible. For Health Decisions, the scope of women’s… Read more »

2017 – Time for a Bold R&D Initiative in Women’s Health

Despite NIH and FDA women’s health policy initiatives previously described in this blog, the list of novel drugs approved by FDA in 2016 includes only one product for a woman-specific health indication. FDA granted accelerated approval in December 2016 for rucaparib (Rubraca™), a Clovis Oncology PARP inhibitor for ovarian cancer. Rubraca is indicated for patients… Read more »

ASRM-NICHD Workshop Focuses on Expanding Access to ART

The 2016 Scientific Congress of the American Society for Reproductive Medicine (ASRM) is in full swing in Salt Lake City. Among the events of greatest interest to the Health Decisions contingent at the congress is “Advancing Science and Practice to Improve Access in Reproductive Care,” a workshop jointly sponsored by ASRM and the Eunice Kennedy… Read more »

Women’s Health Week: Highlighting Unmet Medical Needs

Significant unmet medical needs profoundly affect the lives of hundreds of millions of women worldwide. Women have more than their fair share of healthcare needs for a variety of reasons, including: Women’s healthcare needs vary substantially over the life cycle, from childhood and adolescence through the childbearing years and menopause; this increases the challenge for… Read more »